BACKGROUND: The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) high-performance liquid chromatography (HPLC) method for measuring hemoglobin A1c (HbA1c) serves as a reference standard against which other assays are compared. The DCA 2000 + Analyzer (Bayer Inc., Tarrytown, NY, USA), which uses an immunoassay, is a very popular device for measuring HbA1c levels in pediatric diabetes practices. OBJECTIVE: To determine how HbA1c values measured with the DCA 2000 in a multisite, pediatric diabetes clinic setting compare with corresponding HbA1c values measured in the DCCT/EDIC laboratory. DESIGN/ METHODS: To examine this question, the Diabetes Research in Children Network (DirecNet) used the DCA 2000 in five clinical centers to measure baseline HbA1c levels in 200 youth with type 1 diabetes mellitus (T1DM) (aged 12.5 +/- 2.8 yr) who were participating in an outpatient clinical trial. At the same visit, an additional blood sample was obtained, refrigerated, and shipped to the DCCT/EDIC central laboratory for determination of HbA1c values. RESULTS: The central laboratory HbA1c value averaged 8.0 +/- 0.9% (mean +/- SD), with a median (25th and 75th quartiles) of 7.8% (7.3 and 8.5%, respectively). The DCA 2000 HbA1c values were strongly correlated (r = 0.94, p < 0.001), but significantly higher than DCCT/EDIC central laboratory values with a mean difference of +0.2% (95% confidence interval +0.14 to 0.23%, p < 0.001). There was some variation in the differences between DCA 2000 and central laboratory values at the five clinical centers (p < 0.001) with mean differences ranging between 0.0 and 0.3%, but differences between the two methods did not vary significantly by age or gender. CONCLUSION: Measurements of HbA1c by the DCA 2000 compare favorably with the DCCT/EDIC central laboratory method, albeit with slightly higher values.
BACKGROUND: The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) high-performance liquid chromatography (HPLC) method for measuring hemoglobin A1c (HbA1c) serves as a reference standard against which other assays are compared. The DCA 2000 + Analyzer (Bayer Inc., Tarrytown, NY, USA), which uses an immunoassay, is a very popular device for measuring HbA1c levels in pediatric diabetes practices. OBJECTIVE: To determine how HbA1c values measured with the DCA 2000 in a multisite, pediatric diabetes clinic setting compare with corresponding HbA1c values measured in the DCCT/EDIC laboratory. DESIGN/ METHODS: To examine this question, the Diabetes Research in Children Network (DirecNet) used the DCA 2000 in five clinical centers to measure baseline HbA1c levels in 200 youth with type 1 diabetes mellitus (T1DM) (aged 12.5 +/- 2.8 yr) who were participating in an outpatient clinical trial. At the same visit, an additional blood sample was obtained, refrigerated, and shipped to the DCCT/EDIC central laboratory for determination of HbA1c values. RESULTS: The central laboratory HbA1c value averaged 8.0 +/- 0.9% (mean +/- SD), with a median (25th and 75th quartiles) of 7.8% (7.3 and 8.5%, respectively). The DCA 2000 HbA1c values were strongly correlated (r = 0.94, p < 0.001), but significantly higher than DCCT/EDIC central laboratory values with a mean difference of +0.2% (95% confidence interval +0.14 to 0.23%, p < 0.001). There was some variation in the differences between DCA 2000 and central laboratory values at the five clinical centers (p < 0.001) with mean differences ranging between 0.0 and 0.3%, but differences between the two methods did not vary significantly by age or gender. CONCLUSION: Measurements of HbA1c by the DCA 2000 compare favorably with the DCCT/EDIC central laboratory method, albeit with slightly higher values.
Authors: Cynthia Fritschi; Laurie Quinn; Eileen D Hacker; Sue M Penckofer; Edward Wang; Marquis Foreman; Carol E Ferrans Journal: Diabetes Educ Date: 2012-06-19 Impact factor: 2.140
Authors: Larry Fox; Mariya Dontchev; Katrina Ruedy; Roy Beck; Craig Kollman; Laurel Messer; Julie Coffey; Darrell Wilson; Elizabeth Doyle; William Tamborlane; Michael Steffes Journal: Diabetes Care Date: 2007-01 Impact factor: 19.112
Authors: Maureen Monaghan; Linda Jones Herbert; Jichuan Wang; Clarissa Holmes; Fran R Cogen; Randi Streisand Journal: Health Psychol Date: 2015-02-09 Impact factor: 4.267
Authors: Jamie R Wood; Brett M Kaminski; Craig Kollman; Roy W Beck; Callyn A Hall; Jason P Yun; Eda Cengiz; Michael J Haller; Krishna Hassan; Georgeanna J Klingensmith; William V Tamborlane Journal: J Diabetes Sci Technol Date: 2012-03-01
Authors: Bruce Buckingham; Roy W Beck; William V Tamborlane; Dongyuan Xing; Craig Kollman; Rosanna Fiallo-Scharer; Nelly Mauras; Katrina J Ruedy; Michael Tansey; Stuart A Weinzimer; Tim Wysocki Journal: J Pediatr Date: 2007-08-24 Impact factor: 4.406
Authors: Janne Boone-Heinonen; Rebecca M Sacks; Erin E Takemoto; Elizabeth R Hooker; Nathan F Dieckmann; Curtis S Harrod; Kent L Thornburg Journal: Child Obes Date: 2018-04-06 Impact factor: 2.992
Authors: Elizabeth D Cox; Katie A Fritz; Kristofer W Hansen; Roger L Brown; Victoria Rajamanickam; Kaelyn E Wiles; Bryan H Fate; Henry N Young; Megan A Moreno Journal: Diabetes Res Clin Pract Date: 2014-01-18 Impact factor: 5.602
Authors: David T Liss; Emily A Finch; Dyanna L Gregory; Andrew Cooper; Ronald T Ackermann Journal: Contemp Clin Trials Date: 2015-12-02 Impact factor: 2.226